Lidocaine mucilage-ICG

PreclinicalSmall molecule

SShantou Central Hospital

Lidocaine mucilage-ICG is one of 4 small molecule programs targeting Lidocaine. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LidocaineUnknown status

LidocainePreclinical

Unknown status

Competition

Competitive Landscape

5 competitors in Lidocaine

#DrugCompanyPhaseTrials

Duragesic

CCephalon

Approved

1 2

Phentolamine Mesylate

NNovalar Pharmaceuticals, Inc.

Preclinical

1 3

Lidocaine mucilage-ICG

SShantou Central Hospital

Preclinical

1 4

Lidocaine Lubricant

SSimon Fraser University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lidocaine1 trial

Lidocaine Mucilage-ICG as an Optical Agent for Tumor Delineation During Breast-conserving Surgery

Unknown status·SShantou Central Hospital·N/A·NCT04438577·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Lidocaine mucilage-ICG. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lidocaine mucilage-ICG compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lidocaine mucilage-ICG. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shantou Central Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SShantou Central Hospital

Lidocaine mucilage-ICG

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lidocaine1 trial

References

Drug Info

Quick Facts

Related News